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n developed countries, the availability of highly
active antiretroviral therapy (HAART) has led to
dramatic decreases in morbidity and mortality
due to HIV-1 infection.1 However, as early as 1997,
clinicians noticed morphological changes and met-
abolic complications in some patients treated with
such regimens.2 These changes, resulting from fat
distribution abnormalities, have now been re-
ported in 17%–84% of cases according to cohort
studies and represent a major challenge for long-
term compliance.3,4 They also have a considerable
negative impact on patient psychology and con-
stitute a visible symptom of HIV-1 seropositivity
with all the repercussions on everyday life that
implies. Besides these morphological changes,
metabolic complications such as hyperlipidemia
have also been reported, although consequences in
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Purpose: To analyze the evolution of clinical lipodystrophy (LD) and metabolic
abnormalities in patients continuing to receive HAART versus patients switched to
Trizivir™ (zidovudine, lamivudine, abacavir) after 48 weeks. Method: Patients
treated with HAART >6 months with plasma HIV-1 RNA viral load (VL) <400 copies/
mL and <50 copies/mL at screening were randomly assigned to continue HAART
(103 patients) or to receive Trizivir™ (106 patients). Clinical LD was evaluated using
a standardized patient questionnaire only at baseline, weeks 4 and 8, and then every
8 weeks until Week 48. Laboratory evaluation was performed every 4 weeks.
Results: The proportion of patients exhibiting ≥1 LD symptom at baseline was 40%
in the Trizivir™ arm and 50% in HAART arm (difference not significant). After 48
weeks, the prevalence was 28% and 42% respectively (p = .03), and the median
number of LD symptoms per patient was 2 in the Trizivir™ arm and 4 in the
continued HAART arm (p = .016). Median decreases in cholesterol levels over the
48-week study period were greater in the Trizivir™ arm than in the continued HAART
arm (–0.80 vs. –0.44 mmol/L; p < .001). Median triglyceride levels decreased in the
Trizivir™ arm but increased in the continued HAART arm (–0.17 and +0.01 mmol/L;
p = .006). Suppression of VL was maintained in most patients with no differences
between the two arms. Conclusion: A switch from “standard” HAART to Trizivir™
was associated with an improvement in clinical LD and blood lipid abnormalities
after 48 weeks. Key words: lipids, lipodystrophy, Trizivir™
I terms of cardiovascular risk are not fully known atpresent. These complications have been linked toprotease inhibitor (PI) use; studies performed on
noninfected volunteers receiving PIs found these
patients to have increased cholesterol and triglyc-
eride levels within a few weeks of initiation.5,6 More
recently, some authors have suggested that mito-
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chondrial toxicity related to the use of nucleoside
analogues could be one of the factors leading to fat
redistribution, namely fat atrophy.7,8 Consequent-
ly, alternative PI-sparing regimens have been
developed over the past few years to decrease pill
burden, increase adherence, and limit long-term
metabolic complications. Because many patients
have already received standard HAART regimens,
these new combinations have also been studied as
switch strategies, aimed at limiting the problems
encountered with HAART without compromising
its efficacy. The Trizal study was a randomized,
multicenter, open-label trial in patients with ad-
equate viral suppression that compared the effi-
cacy and tolerance of continued HAART versus a
switch to Trizivir™ (containing fixed doses of
zidovudine, lamivudine, and abacavir; Glaxo-
SmithKline, Marly-le-Roi, France). This report
provides the results of a substudy conducted
during the trial to assess changes in metabolic
abnormalities and clinical lipodystrophy (LD)
through 48 weeks of follow-up.
METHOD
Population
The study was randomized, open label, and
multicenter. Patients were included if they had re-
ceived a triple drug regimen for at least 6 months
and had a documented history of plasma HIV-1
RNA <400 copies/mL, plus plasma RNA <50 cop-
ies/mL within 14 days of enrollment. The initial
treatment consisted either of a combination of two
nucleoside analogue reverse transcriptase inhibi-
tors (NRTIs) + one PI, two NRTIs + one non-
nucleoside analogue reverse transcriptase inhibitor
(NNRTI), or three NRTIs. Patients who had re-
ceived two NRTIs as first-line therapy before mov-
ing to triple therapy were included if their plasma
RNA was <400 copies/mL at that time. A CD4+ T-
cell count <100/mm3 or the presence of > grade 1
hematologic abnormalities were exclusion criteria.
Laboratory Determinations
In each participating center, it was recom-
mended that patients give blood samples in the
morning after 12 hours overnight fasting. All labo-
ratory analyses were performed in the same central
laboratory.
HIV-1 RNA in plasma was measured using the
Roche Amplicor assay (Roche Diagnostics, Basel,
Switzerland) according to the manufacturer’s in-
structions. Lymphocyte subsets were measured on
freshly isolated peripheral blood mononuclear
cells (PBMC) using flow cytometry and mono-
clonal antibodies (Becton Dickinson, Franklin
Lakes, New Jersey, USA). Serum glucose, choles-
terol, and triglyceride levels were measured by
standard clinical laboratory methods as previously
described.9
Evaluation of LD Clinical Symptoms
LD at baseline, Weeks 4 and 8, then every 8
weeks until Week 48 was reported by patients
according to a consensus definition10 with stan-
dardized questionnaires on peripheral atrophy (fa-
cial wasting, arm wasting, limb wasting, buttock
fat loss, prominent veins), fat accumulation (buf-
falo hump, breast enlargement, abdominal fat
changes), and possible LD-related symptoms (dry
skin, dry lips, ingrown toenails, body hair loss,
erectile dysfunction, loss of libido). Body weight
was recorded at the same time points. Anthropo-
metric measurements, dual-energy X-ray absorp-
tiometry (DEXA), and CT scan were not used in
this study.
Statistical Analysis
The primary study objective was virological fail-
ure (defined by HIV-1 RNA ≥400 copies/mL on
two consecutive occasions, or premature discon-
tinuation of randomized study treatment) and was
compared using intent-to-treat analysis (switching
or missing = failure). Distribution of HIV-associ-
ated fat redistribution symptoms was assessed in
both treatment arms by chi-square test. The me-
dian number of symptoms per participant was
compared using a Wilcoxon rank sum test. Percent-
ages of participants in each arm with at least one
emergent symptom or at least one resolved symp-
tom were compared by chi-square test. Percentages
of participants in each arm with at least one emer-
gent symptom without simultaneous resolution of
other symptoms or with resolution of at least one
symptom without simultaneous emergence of
other symptoms were compared by chi-square test.
Weight, CD4+ T-cell count, serum glucose, choles-
terol, and triglycerides in each arm were compared
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using a Wilcoxon rank sum test. A p value <.05 was
considered as significant in each analysis.
RESULTS
Population
A total of 219 patients were randomized, and 209
were included in the trial (106 in the Trizivir™ arm
and 103 in the continued HAART arm). Five pa-
tients in each arm did not initiate treatment due to
incompatibility with entry criteria. The median age
of the 209 patients enrolled was 38 years (range,
20–82). Eighty-eight percent were white Cauca-
sians, 9% were black, and 2% were American His-
panics. Most cases had asymptomatic HIV-1 infec-
tion with a median CD4+ T-cell count of 494 cells/
mm3. The median time on HAART before study
entry was 26 months. The baseline characteristics
of the population are shown in Table 1. No differ-
ences were found between the two arms at baseline
in terms of demographics or laboratory param-
eters.
Forty-five percent of patients were receiving
stavudine (d4T) at baseline versus 38% in the
Trizivir™ and continued HAART arms, respec-
tively.
Treatment Efficacy
Forty-six (22%) participants met the treatment
failure criteria over the 48-week study period: 23 in
the Trizivir™ arm and 23 in the continued HAART
arm. This corresponded to virological failure in 6
cases (Trizivir™, 5; continued HAART, 1) and
switch in 40 cases (Trizivir™, 18; continued
HAART, 22). Using intent-to-treat analysis, we
found that 75% of patients in the Trizivir™ arm
versus 69% in the continued HAART arm had
plasma HIV-1 RNA <50 copies/mL at Week 48
(difference not significant).11
Median increases from baseline in CD4+ T cell
counts were 26 cells/mm3 in both arms. Between
screening and Week 48, two patients (one in the
Trizivir™ arm and one in the continued HAART
arm) progressed from CDC group A to group B.
LD Clinical Symptoms
At baseline, 40% of patients in the Trizivir™ arm
versus 50% in the continued HAART arm com-
plained of at least one LD symptom (difference not
significant). These symptoms comprised either fat
accumulation symptoms only, fat atrophy symp-
toms only, or a combination of both (Table 2). The
Table 1. Baseline characteristics of the included population
Characteristic Trizivir™ (n = 106) Continued HAART (n = 103)
Male, % 80 83
Median age, years 39.5 37
Median weight, kg 68 71
CDC group C, % 20 15
Median CD4, cells/mm3 482 504
Median months on HAART (range) 27 (8–29) 24 (6–44)
HAART at entry, %
2 NRTIs + 1 PI 62 63
2 NRTIs + 1 NNRTI 19 19
3 NRTIs 17 17
1 NRTI + 1 NNRTI + 1 PI 2 0
Median triglycerides, mmol/L 1.6 1.6
Median cholesterol, mmol/L 5.9 5.6
Note: NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = nonnucleoside reverse tran-
scriptase inhibitor.
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median number of LD symptoms per patient was
similar at baseline in both groups (2 in the
Trizivir™ arm and 3 in the continued HAART arm;
p = .139).
At 48 weeks, the proportion of patients with at
least one LD symptom was 28% in the Trizivir™
arm versus 42% in the continued arm. The differ-
ence between the two arms at Week 48 was statisti-
cally significant (p = .03). The evolution from
baseline to Week 48 in the Trizivir™ arm was not
statistically significant (p = .07). At Week 48, the
median number of LD symptoms per participant
with at least one symptom was two in the
Trizivir™ arm versus four in the continued
HAART arm (p = .016).
Subsequent evaluations were performed to ex-
clude possible LD-related symptoms. The propor-
tion of participants exhibiting at least one emergent
LD symptom at Week 48 versus baseline was lower
in the Trizivir™ arm (13%) than in the continued
HAART arm (23%), although the difference did not
reach statistical significance (p = .076). The propor-
tion of participants having at least one LD symp-
tom resolved at Week 48 versus baseline was
higher in the Trizivir™ arm (67%) than in the con-
tinued HAART arm (42%), although this difference
was barely significant (p = .059). At 48 weeks in the
Trizivir™ arm, the emergence of at least one new
LD symptom without other symptom resolution
was observed in 12% of participants; this incidence
reached 20% in the continued HAART arm (p =
.13). At 48 weeks in the Trizivir™ arm, the resolu-
tion of at least one LD symptom without other
symptom emergence was observed in 63% of par-
ticipants compared to 34% of participants in the
continued HAART arm (p = .029).
No significant difference was observed in me-
dian body weight changes in either treatment
group (data not shown).
Evolution of Blood Glucose and Lipid Levels
At Week 48, median changes in blood glucose
levels from baseline were +2.00 mg/dL in the
Trizivir™ arm and +0.50 mg/dL in the continued
HAART arm (p = .492). Median total blood choles-
terol levels over the 48-week study period de-
creased in both groups, although this decrease was
significantly greater in the Trizivir™ arm than in
the continued HAART arm (respectively, –0.80 and
–0.44 mmol/L; p < .001; Figure 1). Median blood
triglyceride levels over the 48-week study period
decreased in the Trizivir™ arm and increased
slightly in the continued HAART arm (respec-
tively, –0.17 and +0.01 mmol/L; p = .006; Figure 2).
Because participants were not systematically
fasting during visits, the evolution of both triglyc-
eride and glucose levels was also analyzed on fast-
ing samples only (52 cases in the Trizivir™ arm and
51 in the continued HAART arm). Conclusions
were similar regarding all sample analyses, al-
though a more pronounced difference was ob-
served in median triglyceride changes between the
two arms (–0.10 vs. +0.18 mmol/L, respectively; p =
.010).
When lipid evolution in terms of changes in tox-
icity grades between baseline and maximum post-
baseline grade through 48 weeks was investigated,
Table 2. Evaluation of clinical lipodystrophy at baseline in the two study arms
Trizivir™ (n = 106) Continued HAART (n = 103)
Patients with lipodystrophy symptoms, n (%) 42 (40) 51 (50)
Classification of symptoms, n (%)
Fat accumulation 6 (6) 7 (7)
Fat atrophy 12 (11) 16 (16)
Fat accumulation and atrophy 9 (8) 16 (16)
Lipodystrophy-related symptoms only 15 (14) 12 (12)
Median number of symptoms/patient 2 3
SWITCHING FROM HAART TO TRIZIVIR AND LIPODYSTROPHY • LAFEUILLADE ET AL. 41
Figure 1. Evolution of blood cholesterol levels (median) from baseline to Week 48 in the two arms. TZV = Trizivir™
arm; CH = continued HAART arm.
Figure 2. Evolution of blood triglyceride levels (median) from baseline to Week 48 in the two arms. TZV = Trizivir™
arm; CH = continued HAART arm.
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9% of patients on Trizivir™ showed a cholesterol
toxicity grade increase versus 29% on continued
HAART (p < .001), and 40% of patients in the
Trizivir™ arm showed a cholesterol toxicity grade
decrease versus 10% on continued HAART (p <
.001).
Regarding triglycerides, 25% of patients on
Trizivir™ showed a toxicity grade increase versus
44% on continued HAART (p < .01), and 22% on
Trizivir™ showed a toxicity grade decrease versus
4% on continued HAART (p = .05).
DISCUSSION
LD and metabolic abnormalities are increasing
obstacles for the effective and safe management of
HIV-1 infection.12,13 Although the precise patho-
physiological mechanisms of these complications
remain to be clarified, antiretrovirals are thought to
play a key role, with varying impact according to
the drugs used.14,15 Consequently, a PI-free combi-
nation that contains less toxic NRTIs for mitochon-
dria is theoretically likely to limit or improve these
anomalies.16 We took advantage of a randomized
trial that tested the virological safety of Trizivir™
switching in patients on standard HAART regi-
mens to perform this substudy aimed at assessing
the consequences of Trizivir™ switching on clinical
LD and metabolic abnormalities. The impact of
Trizivir™ —and in particular lamivudine and
abacavir — on mitochondrial metabolism has been
shown to be less than that of other NRTIs.17 In
addition, this regimen spares PI consequences on
adipogenesis. For the purposes of our substudy,
clinical LD was evaluated using standardized
questionnaires that are easy to implement but do
not provide quantitative measurements. This tool
might be subject to criticism as it gives only a
single-sided view of the problem, that of the pa-
tient. Moreover, different studies that address this
issue have used all available tools or individual
ones from the subjective clinician’s perspective to
the more objective CT/DEXA scans. A validated
definition of HIV LD is still lacking and is needed.
The use of CT and DEXA scans in several studies
has proved difficult to standardize and also has led
to reproducibility problems. The Australian FRAM
study results should be able to clarify the utility of
the different tools.18,19 Moreover, the open-label de-
sign of our study may have impacted positively on
the patients’ perception of their morphologic ab-
normalities, more so for those patients switching
therapy. Forty-eight weeks after switching to
Trizivir™, we observed an important (although
not statistically significant) reduction in the pro-
portion of patients with clinical LD, dropping from
40% at baseline to 28% at Week 48, along with more
frequent symptom resolution without new symp-
tom emergence and less symptoms per patient
than with continued HAART. Significant decreases
in blood cholesterol and triglyceride levels were
observed in the Trizivir™ arm versus the contin-
ued HAART arm. Although the clinical implica-
tions of these metabolic changes were not ad-
dressed during the trial, differences in the
incidence of cardiovascular events in both groups
require an extended assessment.
Various trials have studied the evolution of LD
and metabolic changes after switching a PI-based
therapy to a nevirapine-, efavirenz-, or abacavir-
containing regimen with conflicting results. Some
studies found only an improvement in metabolic
abnormalities after this switch20; this improvement
is also observed when HAART is interrupted.21
Others observed minimal clinical changes in body
fat distribution,22 some of which were probably
related to stavudine replacement.23–25
In conclusion, despite the current absence of spe-
cific treatments for HIV-associated LD syndromes
and the metabolic complications observed with
HAART, our study shows that these complications
could be at least partially limited or reversed by
changing the antiretroviral regimen. This change is
virologically safe if patients are appropriately se-
lected. Further studies, plus an extended follow-up
using a standardized definition of HIV LD, are
now required to confirm these findings.
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